Transcept Pharmaceuticals (TSPT)
Transcept Pharmaceuticals Revenue Growth
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
TSPT Revenue Growth Range, Past 5 Years
| Minimum | -80.00% | Sep 2011 |
| Maximum | 310.2% | Dec 2011 |
| Average | 46.71% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these TSPT related companies
TSPT News
$TSPT Mentioned more than normal on StockTwits - Currently at 5 x average daily social activity
about 2 days ago by TradeIdeasQuant
about 2 days ago by TradeIdeasQuant
RT @HighGrowthFinancial $TSPT Breakout, been posting since down .6% good looking out brother easy money
about 2 days ago by Newbie_Trader
about 2 days ago by Newbie_Trader
@fhmmax $ARNA you are right. Found it on here! "
$TSPT seeks $40.5M in public offering to advance OCD candidate TO-2061, shares slide 14%"
about 11 days ago by BiopharmaPro
about 11 days ago by BiopharmaPro
$TSPT Mentioned more than normal on StockTwits - Currently at 10 x average daily social activity
about 11 days ago by TradeIdeasQuant
about 11 days ago by TradeIdeasQuant
@fhmmax $ARNA dropped on $TSPT doing a stock dilution? did they say how many shares and at what price when it dropped?
about 11 days ago by BiopharmaPro
about 11 days ago by BiopharmaPro
$AMRN $TSPT raised to outperfom http://stks.co/3pO3{372423ee-fd5e-490b-8081-ee1361c10014}
about 12 days ago by fhmmax
about 12 days ago by fhmmax
Listen to $TSPT Q1 2012 earnings call - live at 04:30 PM, ondemand after - http://stks.co/3ono
about 12 days ago by earningscast
about 12 days ago by earningscast
Transcept Pharmaceuticals, (TSPT) Posts Wider than Expected Q1 Loss of 37c/Share
May 14, 4:03PM Street Insider
May 14, 4:03PM Street Insider
Transcept Pharmaceuticals to Present at Two Upcoming Investor Conferences
May 09, 6:58AM PR Newswire
May 09, 6:58AM PR Newswire
$TSPT wonder why the secondary? the conference call implied Purdue as $$ Facility, not shareholders. Waitin for $7.50-80
about 20 days ago by HighGrowthFinancial
about 20 days ago by HighGrowthFinancial
Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
Apr 16, 4:35PM PR Newswire
Apr 16, 4:35PM PR Newswire
Transcept Pharmaceuticals Announces National Product Launch of Intermezzo® by Purdue Pharma L.P.
Apr 05, 6:38AM Benzinga
Apr 05, 6:38AM Benzinga
Transcept (TSPT) Reports New Dosages of Intermezzo Available for Prescription
Apr 05, 6:27AM Street Insider
Apr 05, 6:27AM Street Insider
Transcept Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results
Mar 14, 4:03PM PR Newswire
Mar 14, 4:03PM PR Newswire
Transcept Pharmaceuticals to Present at Two Upcoming Investor Conferences
Feb 29, 8:03AM PR Newswire
Feb 29, 8:03AM PR Newswire
JMP Securities Starts Transcept Pharmaceuticals (TSPT) at Market Outperform
Feb 10, 8:22AM Street Insider
Feb 10, 8:22AM Street Insider
Transcept Pharmaceuticals to Present at Two Upcoming Investor Conferences
Feb 07, 8:05AM PR Newswire
Feb 07, 8:05AM PR Newswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| TSPT | 7.17 | -0.08 | -1.10% | 99.66M |
| TSCO | 99.62 | +0.32 | +0.32% | 7.155B |
| TS | 33.34 | +0.30 | +0.91% | 19.68B |
| TRW | 39.01 | +0.01 | +0.03% | 4.827B |
| TRV | 62.60 | -0.59 | -0.93% | 24.61B |
| TRN | 25.21 | -0.26 | -1.02% | 2.022B |
| TRI | 27.88 | -0.80 | -2.79% | 23.09B |
| TRC | 27.14 | +0.19 | +0.70% | 542.53M |
| TRAC | None | None | None | |
| TR | 22.51 | +0.08 | +0.36% | 1.331B |
